Market capitalization | $2.33b |
Enterprise Value | $2.05b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 8.47 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-87.45m |
Free Cash Flow (TTM) Free Cash Flow | $-65.93m |
Cash position | $288.45m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
7 Analysts have issued a Longboard Pharmaceuticals Inc forecast:
7 Analysts have issued a Longboard Pharmaceuticals Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.01 -0.01 |
0%
0%
|
|
EBITDA | -87 -87 |
65%
65%
|
EBIT (Operating Income) EBIT | -87 -87 |
65%
65%
|
Net Profit | -76 -76 |
50%
50%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company was founded on January 3, 2020 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Kevin Lind |
Employees | 50 |
Founded | 2020 |
Website | www.longboardpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.